Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON48820
NL-OMON48820CompletedPhase 2

An Open Label Phase II Study of Tipifarnib in Advanced Non-Hematological Malignancies with HRAS Mutations. - Tipifarnib Phase II Study-KO-TIP-001

Kura Oncology, Inc0 sites6 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 2
Status
Completed
Enrollment
6
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 64 (—)

Inclusion Criteria

  • •- Subject is at least 18 years of age.
  • •- Subject has a histologically or cytologically confirmed diagnosis of non-hematological malignancy for which there is no curative therapy available
  • •- Subject has a tumor that carries a missense HRAS mutation according to a methodology approved by the Sponsor.
  • •- Subject has measurable disease according to RECIST v1.1 and has relapsed (progressive disease) or is refractory to prior therapy

Exclusion Criteria

  • •- Ongoing treatment with an anticancer agent not contemplated in this protocol.
  • •- Prior treatment (at least 1 full treatment cycle) with an FTase inhibitor.
  • •- Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study

Investigators

Similar Trials

Active, not recruiting
Phase 1
A research study to find ou whether tipifarnib is safe and effective for the treatment of a type of cancer that has a specific genetic mutation and for which there is no curative therapy availableAdvanced Non-Hematological Malignancies with HRAS mutationsMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10071971Term: H-ras gene mutationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004535-12-NLKura Oncology, Inc.36
Active, not recruiting
Phase 1
A research study to find ou whether tipifarnib is safe and effective for the treatment of a type of cancer that has a specific genetic mutation and for which there is no curative therapy availableAdvanced Non-Hematological Malignancies with HRAS mutationsMedDRA version: 18.1Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10071971Term: H-ras gene mutationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 18.1Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004535-12-ESKura Oncology, Inc.63
Active, not recruiting
Phase 1
A research study to evaluate the response rate of tipifarnib in patients with locally advanced unresectable or metastasic, relapsed and/or refractory, squamous non-small cell lung cancer with HRAS mutationssquamous non-small cell lung cancer (SQ-NSCLC)MedDRA version: 20.0 Level: LLT Classification code 10025044 Term: Lung cancer System Organ Class: 100000004864
EUCTR2017-004822-13-ESSpanish Lung Cancer Group (SLCG/GECP)18
Active, not recruiting
Phase 1
A research study to find out whether tipifarnib is safe and effective for the treatment of a type of cancer that has a specific genetic mutation and for which there is no curative therapy available.Advanced non-haematological malignancies with HRAS.MedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10071971Term: H-ras gene mutationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004535-12-GBKura Oncology, Inc.62
Active, not recruiting
Phase 1
A research study to find out whether Tipifarnib is safe and effective for the treatment of a type of a cancer that has a specific genetic mutation and for which there is no curative therapy availableAdvanced non-hematological malignancies with HRAS mutationsMedDRA version: 20.0Level: LLTClassification code 10048683Term: Advanced cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10071971Term: H-ras gene mutationSystem Organ Class: 10018065 - General disorders and administration site conditionsMedDRA version: 20.0Level: PTClassification code 10066474Term: Thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-004535-12-BEKURA ONCOLOGY Inc.62